# OnCo record tazemetostat (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tazemetostat/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tazemetostat" ;
  schema:name "Tazemetostat"@en ;
  schema:description "Tazemetostat was the first EZH2 inhibitor, approved for epithelioid sarcoma and follicular lymphoma in 2020 and withdrawn worldwide in 2026 after secondary blood cancers."@en ;
  schema:url <https://onco.cc/drugs/tazemetostat/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Tazemetostat> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27088941> ;
  schema:citation <https://en.wikipedia.org/wiki/Tazemetostat>, <https://doi.org/10.1038/ng.518> ;
  onco:status "withdrawn" ;
  onco:tag "gap-fill" ;
  onco:modality "Small-molecule EZH2 inhibitor" ;
  schema:alternateName "Tazverik" ;
  onco:approval "US 2020: Epithelioid sarcoma; relapsed FL (EZH2-mutant after 2 lines; wild-type without alternatives)" ;
  onco:acceleratedApproval "US 2020-01-23: Treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection", "US 2020-06-18: Treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. Treatment of adult patients with R/R FL who have no satisfactory alternative treatment options" ;
  onco:cancers <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:targets <https://onco.cc/targets/ezh2/> ;
  onco:companies <https://onco.cc/companies/ipsen/> ;
  onco:trials <https://onco.cc/trials/nct04224493/>, <https://onco.cc/trials/nct05372354/>, <https://onco.cc/trials/nct07407283/> .